Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFor women starting tirzepatide, the most commonly reported side effects are gastrointestinal — nausea, constipation, diarrhoea and indigestion — and they tend to be most noticeable in the first few weeks of treatment or after a dose increase, before settling for most people. These effects are consistent with what the SURMOUNT-1 trial documented, and the NHS tirzepatide medicines page gives a full breakdown of what to watch for. Mounjaro (tirzepatide) is a prescription-only medicine; a clinician assesses whether it is suitable for you before any prescription is issued.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you have collected your first pen, put it in the fridge door, and injected your first 2.5 mg dose on a Sunday morning. By Tuesday you feel mildly nauseous after lunch, and your digestion is slightly off. That is a very typical account. The starter dose exists to give your body time to adjust, its job is settling your system before the dose climbs, and for most women the queasiness is manageable rather than severe.
Nausea is the most frequently reported effect overall. It is often worst in the hour or two after eating a large or fatty meal, which is one reason the clinical guidance that comes with Mounjaro emphasises eating smaller portions and avoiding rich foods early in treatment. Diarrhoea, constipation and indigestion can also appear (sometimes alternating) and burping or feeling prematurely full is common. Fatigue and mild headache show up less often but are documented.
These are not unique to women, but the experience of them can differ. Women in the SURMOUNT-1 trial who reported nausea generally did so at the start of each new dose level, with symptoms improving over one to two weeks. Staying well hydrated matters here; the NHS tirzepatide page advises contacting a GP or pharmacist if vomiting or diarrhoea is severe or prolonged enough to affect hydration.
If you want a broader picture of how these effects compare between men and women, our full Mounjaro side effects guide covers the general profile in detail.
Some considerations carry extra weight for women specifically, and it is worth knowing them before you start rather than discovering them mid-treatment.
Oral contraceptives and absorption. Tirzepatide slows gastric emptying, which can reduce how much of an oral contraceptive pill your body absorbs. NHS guidance is clear: for the first four weeks of Mounjaro treatment and for four weeks after every dose increase, women on the pill should use an additional non-oral method of contraception, condoms, for example. This does not apply if you use a patch, implant, injection or coil. If you are considering HRT, NHS England advises discussing transdermal options (patches or gels) with your doctor for the same absorption reason.
Hair thinning. Some women report a degree of hair shedding during significant weight loss on tirzepatide, and our dedicated page on whether Mounjaro causes hair loss in women explains what the evidence says and what helps. This is believed to be largely related to the physiological stress of rapid calorie reduction rather than a direct drug effect, a condition called telogen effluvium, and it is usually temporary.
Sleep. A smaller number of women mention disrupted sleep, particularly early in treatment. If that is something you are experiencing, our page on whether insomnia is a side effect of Mounjaro walks through the current evidence.
Pregnancy and conception. Mounjaro is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. Women of childbearing age should be using effective contraception throughout treatment. Our dedicated page on Mounjaro and pregnancy covers the guidance in full.
Most side effects are mild, predictable and temporary. A smaller set of symptoms require prompt attention, and knowing them in advance means you will not hesitate if they appear.
Severe abdominal pain that reaches the back. This is the key symptom to take seriously. In January 2026, the MHRA issued a Drug Safety Update confirming that acute pancreatitis is a known (though infrequent) serious risk with GLP-1 medicines. The MHRA Drug Safety Updates page has the full communication. If you develop severe, persistent stomach pain that radiates to your back, with or without vomiting, stop treatment and seek urgent medical care.
Signs of dehydration. Prolonged vomiting or diarrhoea can dehydrate you quickly. Symptoms (dry mouth, dizziness, very dark urine, passing very little) are a reason to contact your GP or go to an urgent treatment centre promptly. Kidney function can be affected by severe dehydration on these medicines.
Gallbladder symptoms. Rapid weight loss of any cause raises the risk of gallstones. Sudden upper-right abdominal pain, especially after eating, is worth reporting to a doctor.
Allergic reaction. Rash, swelling of the face or throat, difficulty breathing, call 999 or go to A&E immediately.
Any suspected side effect can be reported to the MHRA via the Yellow Card scheme, and patient reports are actively reviewed. If you have questions about a specific symptom mid-treatment, our prescribers are available for aftercare seven days a week, you can reach the team via our contact page.
Side-effect conversations are built into every consultation at nume, not bolted on as an afterthought. A GPhC-registered prescriber reads your health history and answers before anything is issued, no automated approvals, a real clinician each time. That means any factors that raise your individual risk (a history of pancreatitis, current oral contraceptive use, plans around conception) are considered before you start, not discovered afterwards.
For women specifically, questions about contraception, HRT and cycle changes come up regularly; our clinical team is used to them. If it turns out Mounjaro suits you and treatment begins, the aftercare runs seven days a week throughout. You can explore the full treatment options and start a free consultation when you are ready, our prescribers discuss side-effect suitability as a core part of that process, not as a box-tick at the end.
For a broader look at how men's experiences compare, see our page on Mounjaro side effects in men.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.